Big Pharma
26 February 2026 In a decision with implications for biotechnology licensing and pharmaceutical manufacturing, the Ninth Circuit has rejected a ‘sweeping’ royalty trigger from a lower court.
24 February 2026
20 February 2026
11 February 2026
10 February 2026
Latest Features
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
More News
5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.
4 February 2026 The new hire, who has clients in pharma and medical devices and diagnostics, will lead the Dublin office's IP & Technology practice.
3 February 2026 Nominations are open for the Life Sciences Patent Network's 2026 awards in Boston, including six new categories and winners selected by leading industry experts.
3 February 2026 As legislative activity in life sciences increases, in-house teams are struggling to keep up. Experts share their sources and strategies for monitoring developments, coordinating internally, and knowing when to engage.
29 January 2026 A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.
28 January 2026 The rise of fake online stores selling counterfeit pharmaceuticals is driving a surge in domain name disputes, forcing major brands to defend revenue and reputation.
27 January 2026 As quantum-enabled innovation accelerates, patentability will hinge on predictability, disclosure, and modality-specific claim drafting in an increasingly unforgiving enablement landscape, explain Ray Miller and Joseph Wolfe of DLA Piper
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox